LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Levels of Circulating Cell-Free DNA Predict Risk of Developing Dementia

By LabMedica International staff writers
Posted on 12 Oct 2022
Image: Fragments of cell free nucleic acids (DNA and RNA) in human blood (Photo courtesy of www.123rf.com)
Image: Fragments of cell free nucleic acids (DNA and RNA) in human blood (Photo courtesy of www.123rf.com)

A test that measured the amount of cell-free DNA fragments in the blood was able to identify individuals at higher risk of developing dementia, worsening cognition. and frailty.

Altered cellular equilibrium, seen in cognitive decline and frailty, leads to cell death and turnover, releasing circulating cell-free DNA (ccf-DNA). In a recently published study, investigators at Johns Hopkins University (Baltimore, MD, USA) determined whether serum genomic cell-free DNA (ccf-gDNA) was associated with physical and cognitive decline in older adults.

For this study, the investigators used digital PCR to analyze blood samples from 631 individuals with an average age of 79 years who showed no cognitive impairment when the study began. An array of cognitive and physical traits, risk of dementia, global cognition, and frailty at or nearest the time of blood draw were compared to ccf-DNA levels, with adjustment for age, sex, race, and education. The data gathering period lasted for eight years.

Results across the group showed that higher ccf-gDNA levels were associated with lower global cognition score and slower gait speed at the evaluation nearest to blood draw. Furthermore, higher ccf-gDNA levels were associated with increased odds of incident dementia. Individually, higher levels of ccf-gDNA were associated with steeper general cognitive decline and worsening frailty over the eight years of follow up.

“These ccf-gDNA fragments may trigger long-term chronic inflammatory reactions that have previously been linked to the premature destruction and aging of tissues and organs, including the brain,” said senior author Dr. Peter Abadir, associate professor of geriatric medicine and gerontology at Johns Hopkins University. “The body sees these ccf-gDNA fragments as something that needs to be removed, therefore the body’s immune system is running at a higher rate than it should. Such immune system overdrive may be a factor in identifying the onset of dementia.”

Results of the study were published in the October 11, 2022, issue of the Journal of Alzheimer’s Disease.

Related Links:
Johns Hopkins University 

Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
ESR Analyzer
TEST1 2.0

Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more